A new Israeli startup is aiming to redefine beer’s role in the beverage market by combining brewing science with the fast-growing wellness segment. Rosalind Bioculture, founded by Menashe Haskin, CEO of Rosalind Bioculture, and Dr. Moran Gendelman, CTO of Rosalind Bioculture, is developing a novel yeast capable of producing NAD+ during fermentation—positioning beer as a potential functional beverage rather than purely a recreational product.
The company’s approach centers on enabling beer yeast to naturally generate NAD+ (nicotinamide adenine dinucleotide), a derivative of vitamin B3 that plays a key role in cellular energy production, metabolism, and DNA repair. Scientific research highlights that NAD+ levels decline with age, which has been linked to reduced cellular performance and various age-related conditions. By embedding this compound directly into the brewing process, Rosalind aims to deliver a daily intake of NAD+ through a standard beer serving without the need for additives.
Unlike conventional functional beverages that rely on external fortification, Rosalind’s method integrates the health component directly into fermentation. Using classical microbiological techniques rather than invasive genetic modification, the company has engineered yeast strains that both increase NAD+ output and simultaneously reduce alcohol production. Initial test batches have achieved alcohol levels between 2.5% and 3%, with ongoing development targeting sub-2% variants—aligning with the global shift toward lower-alcohol consumption, particularly among younger consumers.
The innovation comes at a time when alcohol’s negative health perception continues to grow, creating demand for alternatives that balance enjoyment with perceived wellness benefits. Rosalind’s dual proposition—health functionality and reduced alcohol—directly addresses this trend, potentially opening a new category within the beer segment.
Commercially, the startup is pursuing a B2B model rather than launching its own brand. It plans to supply its proprietary yeast to breweries, enabling them to produce differentiated products under their own labels. This strategy reflects both capital efficiency and the increasing appetite among brewers for innovation that can capture evolving consumer preferences.
The company remains in an early stage, having raised approximately USD 310,000 in pre-seed funding and currently producing pilot batches in collaboration with a regional brewery. It is now entering discussions with brewing partners in Israel and internationally to scale trials and validate market potential.
Recognition has already followed, with Rosalind winning the 2024 Coller Startup Competition at Tel Aviv University, underlining growing investor and industry interest in food-tech solutions that intersect with health and sustainability.
While regulatory and consumer acceptance questions remain—particularly around positioning alcohol as a health-linked product—the concept reflects a broader shift in the beverage industry toward functional innovation. If successful, Rosalind’s technology could mark a significant step in redefining beer’s place within the modern wellness landscape.
